









Markets
/
Stocks
/
nasdaq-kzr
/

Kezar Life Sciences Inc

KZR

6.100USD

+0.010+0.16%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

44.63MMarket Cap

LossP/E TTM



Kezar Life Sciences Inc

6.100

+0.010+0.16%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kezar Life Sciences Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kezar Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

117 / 407

Overall Ranking

248 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Hold

Current Rating

6.000

Target Price

-1.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kezar Life Sciences Inc Highlights

StrengthsRisks

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -0.63, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.68M shares, decreasing 19.44% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 87.28K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.93, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.93

Change



Financials

7.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Kezar Life Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.39, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.63, which is -89.08% below the recent high of -0.07 and -11368.03% above the recent low of -72.17.

Score

Industry at a Glance

Previous score

7.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 6.33, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Kezar Life Sciences Inc is 6.00, with a high of 7.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Hold

Current Rating

6.000

Target Price

-1.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Kezar Life Sciences Inc

KZR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.70, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 6.97 and the support level at 4.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.18

Change

0.52

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.048

Neutral

RSI(14)

71.305

Buy

STOCH(KDJ)(9,3,3)

37.204

Sell

ATR(14)

0.320

Low Volatility

CCI(14)

-122.949

Sell

Williams %R

38.961

Buy

TRIX(12,20)

1.920

Sell

StochRSI(14)

3.067

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

6.152

Sell

MA10

6.166

Sell

MA20

5.622

Buy

MA50

4.578

Buy

MA100

4.420

Buy

MA200

4.754

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 63.96%, representing a quarter-over-quarter decrease of 9.24%. The largest institutional shareholder is The Vanguard, holding a total of 276.23K shares, representing 3.77% of shares outstanding, with 0.46% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

720.00K

Suvretta Capital Management, LLC

716.76K

BML Capital Management LLC

635.18K

+55.63%

Equal Talent Investments, Ltd.

616.50K

Avidity Partners Management LP

502.60K

Stonepine Capital Management, LLC

377.24K

+122.09%

The Vanguard Group, Inc.

Star Investors

276.23K

OrbiMed Advisors, LLC

192.70K

Adar1 Capital Management LLC

147.40K

Acadian Asset Management LLC

133.53K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.47, which is equal to the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.